Olmesartan Medoxomilo+ Hidroclorotiazida Blixie (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil/hydrochlorothiazide is an antihypertensive combination that lowers elevated blood pressure through dual mechanisms.

• Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension.
• High systolic blood pressure: helps achieve target systolic values when monotherapy is insufficient.
• High diastolic blood pressure: contributes to diastolic control as part of a comprehensive regimen.

• Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume. The combined effect results in reduced peripheral resistance and lower blood pressure.

Common Side Effects

• Dizziness: feeling light‑headed, especially after the first doses.
• Headache: mild to moderate intensity.
• Fatigue: general tiredness or lack of energy.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: mild changes in potassium or sodium levels.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Renal impairment: worsening kidney function, especially in patients with pre‑existing disease.
• Hyperkalemia: elevated potassium levels that may affect heart rhythm.
• Angioedema: swelling of face, lips, tongue, or throat.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, clinicians should consider several safety aspects.

• Blood pressure monitoring: ensure target levels are achieved without excessive drops.
• Renal function assessment: check serum creatinine and eGFR periodically.
• Electrolyte surveillance: monitor potassium and sodium, especially when combined with other diuretics.
• Pregnancy caution: avoid use unless clearly needed, as safety data are limited.
• Hepatic impairment: use with caution in patients with severe liver disease.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxomil/hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid)

• Aliskiren: combined use can cause excessive potassium rise and renal dysfunction.
• Potassium‑sparing diuretics (e.g., spironolactone): increase risk of hyperkalemia.
• NSAIDs: may blunt antihypertensive effect and worsen renal function.
• Lithium: can raise lithium levels, leading to toxicity.
• ACE inhibitors: concurrent use may precipitate severe hypotension and renal impairment.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may require dose adjustment to avoid hypotension.
• Loop diuretics: monitor electrolytes and volume status.
• Antidiabetic agents: blood glucose may improve, necessitating dose changes.
• CYP450 inhibitors (e.g., fluconazole): may increase olmesartan levels.
• Antacids containing aluminum or magnesium: may reduce absorption of olmesartan.